This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

9 Stocks Hit 52-Week Highs: WMB, AEO, T, CRUS, TSM, AZO, MJN, WPI, RTN

Stock quotes in this article: AEO, T, RTN, TSM, WPI, MJN, CRUS, WMB, AZO

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

AutoZone

"We are upgrading AZO to Overweight for the following reasons: (1) AZO's accelerated investment into its commercial initiative provides a baseline 3% comp for the medium term (any DIY gain is gravy on top); (2) the company's cost discipline and commitment to maintain leverage to drive the buyback enhances the stock/earnings revision risk-reward (even if 'only a 3 comp'); (3) given these factors we believe valuation remains attractive (relatively and absolutely); and (4) unfavorable discretionary retail stock seasonality is looming and we favor adding exposure to a defensive GARP stock with idiosyncratic topline opportunities and secular (albeit more modest than prior) tailwinds," JPMorgan analysts wrote in a report Tuesday.

Shares of AutoZone hit a 52-week high Thursday of $395.12. The stock's 52-week low of $266.25 was set on Aug. 8.

AutoZone has a forward P/E of 14.33; the average for specialty retailers is 16.13. For comparison, O'Reilly Automotive (ORLY) has a higher forward P/E of 19.38.

Twelve of the 22 analysts who cover AutoZone rated it buy; 10 analysts gave the stock a hold rating.

TheStreet Ratings gives AutoZone a B- grade with a buy rating and $498.75 price target. The stock has risen 19.86% year to date.






Watson Pharmaceuticals

The drug company acquired Swiss generic drug company Actavis on Wednesday for about $5.6 billion.

"We are raising our sales and EPS estimates as well as our price target for WPI shares following the company's announced acquisition of Actavis for $5.6bn with an additional 5.5mm WPI share earn-out," JPMorgan analysts wrote in a report Thursday. "In our view, the Actavis acquisition represents a transformational move for Watson that will solidify the company's US business and significantly propel its international presence. The potential accretion from the deal appears well above our initial estimates (over 30% accretive to 2013 earnings per share ), Actavis' diversification is greater than we had anticipated and the combined entity offers a number of potential levers for further EPS upside/growth. Along these lines, we are reiterating our overweight rating on WPI shares and see the potential for significant further upside from current levels."

Shares of Watson Pharmaceuticals hit a 52-week high of $75.95 on Thursday. The stock's 52-week low of $55 was set on Jan. 24.

Watson Pharmaceuticals' forward P/E is 11.2; the average for pharmaceutical companies is 22.56. For comparison, Perrigo (PRGO) has a higher forward P/E of 19.27.

Seventeen of the 24 analysts who cover Watson Pharmaceuticals rated it buy; seven analysts gave the stock a hold rating.

TheStreet Ratings gives Watson Pharmaceuticals an A grade with a buy rating and $82.18 price target. The stock has risen 24.38% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

-- Written by Alexandra Zendrian



>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to: tips@thestreet.com.

>To follow the writer on Twitter, go to Alexandra Zendrian.

5 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,042.90 -28.32 -0.17%
S&P 500 1,972.29 -5.51 -0.28%
NASDAQ 4,493.39 -12.4620 -0.28%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs